Autres langues Polaris Group

Actions

6550

KYG7171A1085

Cours en clôture Taiwan S.E. Autres places de cotation 00:00:00 06/06/2024			Varia. 5j.	Varia. 1 janv.
73,6 ^TWD	+2,08 %		+3,23 %	-2,65 %

15/05	Polaris Group retire volontairement de la FDA le protocole d'essai clinique de phase III pour le cancer du foie	CI
14/05	Polaris Group annonce un changement de membre du comité de rémunération	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA	15/05
Polaris Group Announces Change of the Member of Compensation Committee	14/05
Polaris Group Announces Change of the Member of Audit Committee	03/05
Polaris Group acquired an additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	23/12
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth	22/12
Polaris Group Announces the Appointment of K Evin Wu	21/12
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	21/12
Polaris Group agreed to acquire additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	21/12
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	04/12
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	04/12
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study	30/11
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan	29/11
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	17/11
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	17/11
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11/11
Polaris Group announced a financing transaction	06/10/23
Polaris Group Appoints K.C. Tsai as Compensation Committee Member	26/09/23
TDW HK Limited announced that it has received $17 million in funding from Polaris Group	26/09/23
Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member	29/08/23
Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director	29/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Polaris Group

Actions

6550

KYG7171A1085

Autres langues

Filtres